MaxCyte, Inc. Notice of AGM and 2016 Annual Report and Accounts (4800C)

TIDMMXCT

RNS Number : 4800C

MaxCyte, Inc.

13 April 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of AGM and 2016 Annual Report and Accounts

Maryland, USA - 13 April 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, gives notice that copies of the 2016 Annual Report and Accounts and the Notice of Annual General Meeting have been sent to shareholders. These documents are available on the "Investors" section of the Company's website at www.maxcyte.com.

Further copies of the Annual Report will be available from the Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878, USA.

MaxCyte also announces that its Annual General Meeting of Stockholders is planned to be held on 31 October 2017. Formal notice and resolutions, along with the Annual Meeting Proxy Card, will be circulated on or about 10 September 2017 to Stockholders of record on or about that date.

For further information please contact:

 
 MaxCyte                                [phone] 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer 
 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Freddy Crossley (Corporate 
  Finance) 
  Fabien Holler 
  Duncan Monteith 
  Tom Salvesen (Corporate Broking)      [phone] 
 Financial PR Adviser                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Chris Welsh 
  Lindsey Neville 
 

About MaxCyte

MaxCyte (LSE: MXCT) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialise cell-based medicines.

MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information, visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSOKNDBDBKDFQD

(END) Dow Jones Newswires

April 13, 2017 08:00 ET (12:00 GMT)